Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/46225| Title: | Utilising the Benefit Risk Assessment of Vaccines (BRAVE) toolkit to evaluate the benefits and risks of Vaxzevria in the EU: a population-based study | Authors: | Gonzalez Dorta, Hector VERBEECK, Johan CREVECOEUR, Jonas Morales, Daniel LOEDY, Neil Cohet, Catherine Willem , Lander MOLENBERGHS, Geert HENS, Niel Kurz, Xavier Quinten, Chantal ABRAMS, Steven |
Issue Date: | 2025 | Publisher: | Source: | The Lancet. Digital health, 7 (5) (Art N° 100861) | Abstract: | Background Several COVID-19 vaccines have been licensed. To support the assessment of safety signals, we developed a toolkit to support COVID-19 vaccine monitoring and benefit-risk assessment. We aim to show the application of our toolkit in the EU using thrombosis with thrombocytopenia syndrome (TTS) associated with the Vaxzevria (AstraZeneca) vaccine as a use case. | Document URI: | http://hdl.handle.net/1942/46225 | e-ISSN: | 2589-7500 | DOI: | 10.1016/j.landig.2025.02.001 | Rights: | 2025 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. | Category: | A1 | Type: | Journal Contribution |
| Appears in Collections: | Research publications |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| PIIS2589750025000251.pdf | Published version | 213.48 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.